Investors

A New Investment Frontier in Genetic Psychiatry

Cognigenics offers investors access to a high-potential, de-risked therapeutic platform at the intersection of neuroscience, RNA therapeutics, and noninvasive delivery.

Market Rationale

  • ~1 million patients with Parkinson’s in the U.S.; 40–50% of advanced-stage patients develop psychosis or severe anxiety
  • No targeted RNA-based therapies exist for psychiatric indications
  • First-mover advantage in intranasal siRNA delivery targeting CNS receptors

Capital Use

Next-stage capital will fund:

  • COG-301 NEW design and testing (in vitro and in vivo)
  • Final GLP tox and dose-ranging studies
  • IND submission and Phase I trial readiness
  • Expanded IP filings and manufacturing scale-up

Join Us

We’re building a new modality for psychiatry—and a platform for durable, precision CNS therapeutics.